Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Shareholder Meeting (November 2007)
16 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 28, 2007
Slide 1: AGM 2007
For personal use only AGM 2007 Aki von Roy Chairman
Slide 2: Chairman's Address
Chairman's Address I would like to welcome everybody to the Annual General Meeting of Phylogica. My name is Bruce McHarrie and I am acting as Chairman for this meeting as Aki von Roy is unable to For personal use only travel due to the flu. In particular, I would especially like to thank our loyal s
Slide 3: AGM 2007 - Stewart Washer, CEO
For personal use only AGM 2007 STEWART WASHER CEO
Slide 4: Phylomer drug discovery technology to create new drugs for key diseases
For personal use only Phylogica is exploiting its unique Phylomer™ drug discovery technology to create new drugs for key diseases
Slide 5: Next Generation Drug Space
For personal use only Next Generation Drug Space Pharma have aging drug pipelines with patent expiry pressure. Hence they are hungry for new drug discovery technologies (protein based drugs on the rise) Pharma aggressively pursuing deals and/or acquiring protein/scaffold companies (valuable space) P
Slide 6: Corporate Activity of Peers
For personal use only Corporate Activity of Peers Dec 2006 May 2007 Oct 2007 Domantis Evogenix Haptogen acquired by GSK acquired acquired (US$453m) by Peptech by Wyeth (US$123m) (value undiscl) Sept 2007 May 2006 Feb 2007 Adnexus CAT acquired by Avidia acquired acquired Astrazeneca by Amgen by BMS (
Slide 7: Phylomer Advantages
Phylomer® Advantages Unlike other protein-based scaffolds which allow screening random peptides in context of one structural class, Phylomer® peptide libraries can be viewed as the most comprehensive For personal use only collection of protein folds/ scaffolds found in nature
Slide 8: Benefits over Existing Drugs
Benefits over Existing Drugs Phylomer® drugs offer significant advantages For personal use only beyond current antibody therapies; - Able to hit Intracellular targets - Reduced cost of goods - No antibody intellectual property royalty stack - Alternative patient friendly delivery potential
Slide 9: PYC Report Card
PYC Report Card PYC compared to peers that have multiple valuable deals and/or For personal use only trade sale in hundreds millions $US What we need to complete to reach the value sweet spot Key Event Peers PYC Multiple targets hit YES YES Strong IP position and FTO YES YES In-vitro bio-validation
Slide 10: Drug Development/Clinical Milestones
For personal use only Drug Development/Clinical Milestones Burns/wound healing drug will enter human trials next year - First Phylomer™ drug in humans - Funded within current cash reserves - Unlocks value of Phylomer® drug technology - Major value adding event RA drugs will move into key disease mod
Slide 11: Commercial Milestones
Commercial Milestones Phylomer drugs developed with Opsona will complete For personal use only tests in models of inflammatory bowel disease and kidney damage A major pharma company is testing our Phylomer technology in-house and if successful, we will be entering a commercial deal Several other dea
Slide 12: Phylogica 2007
Phylogica 2007 – Appoints Dr Doug Francis as Head of Drug Development (ex-Pharmaxis) – Appoints Dr Mark Pierce as Director – former Senior Vice President of Clinical Research at For personal use only Pfizer – Awarded grant to develop drugs to prevent brain damage associated with traumatic brain inju
Slide 13: Board and Management
Board and Management a blend of experience and expertise For personal use only Mr Joachim (Aki) von Roy – Chairman • Former President of Bristol-Myers Squibb, Europe • Over 30 years international experience in pharmaceutical companies, including Schering AG and Bristol-Myers Squibb Dr Mark Pierce –
Slide 14: Board and Management
Board and Management a blend of experience and expertise For personal use only Dr Paul Watt – VP Technology Development • Commonwealth overseas scholarship recipient, completed his doctorate at the University of Oxford • Post Doctoral appointments at Oxford and Harvard Universities •Over 10 years co
Slide 15: Summary
For personal use only Summary PYC trading at significant discount to peers The sector is in play PYC focused on delivering key milestones to achieve value realisation in this hot sector
Slide 16: www.phylogica.com
For personal use only www.phylogica.com